Skip to Main Content
Skip Nav Destination

Chromatin Remodeling Governs Clinical Response to EZH2/EZH1 Inhibition

February 29, 2024

Major Finding: Clinical responses to the EZH1/2 inhibitor valemetostat are driven by the loosening of chromatin structure.

Concept: Increased accessibility induces expression of tumor suppressor genes, which were previously silenced.

Impact: These data suggest that reprogramming the cancer epigenome could lead to sustained clinical benefit.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal